Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Portopulmonary hypertension

Lewis J Rubin, MD
Section Editor
Jess Mandel, MD
Deputy Editor
Geraldine Finlay, MD


Portopulmonary hypertension (PPHTN) refers to pulmonary arterial hypertension that is associated with portal hypertension; it is a well recognized complication of chronic liver disease [1-3]. In this topic review, the definition, classification, epidemiology, and pathogenesis of PPHTN are discussed. In addition, its clinical presentation, diagnosis, treatment, and prognosis are reviewed. Hepatopulmonary syndrome, a separate but related condition characterized by hypoxemic respiratory insufficiency due to increased intrapulmonary shunting, is discussed separately [1,4,5]. (See "Hepatopulmonary syndrome in adults: Prevalence, causes, clinical manifestations, and diagnosis".)


Portopulmonary hypertension (PPHTN) is considered present when pulmonary arterial hypertension (PAH) exists in a patient who has coexisting portal hypertension, and no alternative cause of the PAH exists (eg, collagen vascular disease, congenital heart disease, or certain drugs) [1].

PAH is defined according to right heart catheterization [6]:

Mean pulmonary artery pressure (mPAP) >25 mmHg at rest

Pulmonary capillary wedge pressure (PCWP) <15 mmHg

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Oct 04, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Rodríguez-Roisin R, Krowka MJ, Hervé P, et al. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24:861.
  2. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127:437.
  3. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520.
  4. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461.
  5. Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest 2003; 123:562.
  6. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.
  7. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34.
  8. Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3:494.
  9. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 71:543.
  10. Taura P, Garcia-Valdecasas JC, Beltran J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996; 83:675.
  11. Plevak D, Krowka M, Rettke S, et al. Successful liver transplantation in patients with mild to moderate pulmonary hypertension. Transplant Proc 1993; 25:1840.
  12. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37:401.
  13. Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52:1355.
  14. Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006; 44:1502.
  15. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 17:17.
  16. Cohen MD, Rubin LJ, Taylor WE, Cuthbert JA. Primary pulmonary hypertension: an unusual case associated with extrahepatic portal hypertension. Hepatology 1983; 3:588.
  17. Lebrec D, Capron JP, Dhumeaux D, Benhamou JP. Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 1979; 120:849.
  18. Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 1996; 17:151.
  19. Egermayer P, Town GI, Peacock AJ. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999; 54:161.
  20. Maruyama T, Ohsaki K, Shimoda S, et al. Thromboxane-dependent portopulmonary hypertension. Am J Med 2005; 118:93.
  21. Nichols WC, Koller DL, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15:277.
  22. Deng Z, Haghighi F, Helleby L, et al. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33. Am J Respir Crit Care Med 2000; 161:1055.
  23. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000; 67:737.
  24. Kimura N, Matsuo R, Shibuya H, et al. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 2000; 275:17647.
  25. NAEYE RL. "Primary" pulmonary hypertension with coexisting portal hypertension. A retrospective study of six cases. Circulation 1960; 22:376.
  26. Edwards BS, Weir EK, Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10:1233.
  27. Matsubara O, Nakamura T, Uehara T, Kasuga T. Histometrical investigation of the pulmonary artery in severe hepatic disease. J Pathol 1984; 143:31.
  28. Pietra GG. Histopathology of primary pulmonary hypertension. Chest 1994; 105:2S.
  29. Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 1996; 17:1.
  30. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17:492.
  31. Kuo PC, Plotkin JS, Johnson LB, et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 112:980.
  32. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352:719.
  33. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336:111.
  34. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580.
  35. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76.
  36. Frank H, Mlczoch J, Huber K, et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112:714.
  37. Provencher S, Herve P, Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130:120.
  38. Rich S. The medical treatment of primary pulmonary hypertension. Proven and promising strategies. Chest 1994; 105:17S.
  39. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96:2782.
  40. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs 1998; 56:989.
  41. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112:485.
  42. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409.
  43. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296.
  44. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343.
  45. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740.
  46. Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30:641.
  47. Plotkin JS, Kuo PC, Rubin LJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65:457.
  48. Tan HP, Markowitz JS, Montgomery RA, et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl 2001; 7:745.
  49. Kett DH, Acosta RC, Campos MA, et al. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001; 7:645.
  50. Awdish RL, Cajigas HR. Early initiation of prostacyclin in portopulmonary hypertension: 10 years of a transplant center's experience. Lung 2013; 191:593.
  51. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1184.
  52. Findlay JY, Plevak DJ, Krowka MJ, et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 1999; 5:362.
  53. Halank M, Miehlke S, Hoeffken G, et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77:1775.
  54. Kuntzen C, Gülberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128:164.
  55. Grander W, Eller P, Fuschelberger R, Tilg H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006; 36 Suppl 3:67.
  56. Stähler G, von Hunnius P. Successful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest 2006; 36 Suppl 3:62.
  57. Neuhofer W, Gülberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006; 36 Suppl 3:54.
  58. Hinterhuber L, Graziadei IW, Kähler CM, et al. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2:1039.
  59. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25:502.
  60. Hoeper MM, Seyfarth HJ, Hoeffken G, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007; 30:1096.
  61. Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139:109.
  62. Savale L, Magnier R, Le Pavec J, et al. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2013; 41:96.
  63. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005; 24:498.
  64. Latiff K, Meanger J, Mills J, Ghildyal R. Sequence and structure relatedness of matrix protein of human respiratory syncytial virus with matrix proteins of other negative-sense RNA viruses. Clin Microbiol Infect 2004; 10:945.
  65. Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28:563.
  66. Halank M, Marx C, Miehlke S, Hoeffken G. Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 2004; 39:1222.
  67. Minder S, Fischler M, Muellhaupt B, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24:703.
  68. Koneru B, Ahmed S, Weisse AB, et al. Resolution of pulmonary hypertension of cirrhosis after liver transplantation. Transplantation 1994; 58:1133.
  69. De Wolf AM, Scott VL, Gasior T, Kang Y. Pulmonary hypertension and liver transplantation. Anesthesiology 1993; 78:213.
  70. Schott R, Chaouat A, Launoy A, et al. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115:1748.
  71. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10:174.
  72. Khaderi S, Khan R, Safdar Z, et al. Long-term follow-up of portopulmonary hypertension patients after liver transplantation. Liver Transpl 2014; 20:724.
  73. Sithamparanathan S, Nair A, Thirugnanasothy L, et al. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. J Heart Lung Transplant 2017; 36:770.
  74. Rajaram P, Parekh A, Fisher M, et al. Comparison of Post-Liver Transplantation Outcomes in Portopulmonary Hypertension and Pulmonary Venous Hypertension: A Single-Center Experience. Transplant Proc 2017; 49:338.
  75. Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012; 141:906.
  76. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178:637.